Research Article


DOI :10.26650/jchild.2024.1584011   IUP :10.26650/jchild.2024.1584011    Full Text (PDF)

Evaluation of Patients with Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency: A Single-Center Experience

Sevgi Bilgic EltanSelcen BozkurtAsena Pınar SeferEzgi Yalçın GüngörenMelek Yorgun AltunbaşSalim CanRazin AmirovNecmiye ÖztürkSafa BarışAhmet ÖzenElif Karakoç Aydıner

Objective: This study aimed to evaluate the clinical, immunological, and prognostic features of seven patients diagnosed with Adenosine Deaminase Deficiency Severe Combined Immunodeficiency (ADA-SCID) at Marmara University. The aim of this study was to enhance the recognition and management of this condition, which is characterized by impaired lymphocyte development and early severe infections.

Methods: This retrospective study included seven patients with ADA-SCIDs who were monitored from 2012 to 2024. Patient data, including demographics, clinical findings, laboratory results, and imaging, were retrieved from hospital records. Diagnostic criteria focused on ADA enzyme activity and genetic mutations. Treatment regimens, such as immunoglobulin replacement, antimicrobial prophylaxis, enzyme replacement therapy, and hematopoietic stem cell transplantation (HSCT), were documented. Statistical analyses were performed using descriptive methods.

Results: The cohort (6 males, 1 female) presented a median age at diagnosis of 3 months. Consanguinity was observed in 86% of cases. Key symptoms included lymphopenia, recurrent infections, thymus absence, and systemic manifestations. Six patients received HSCT, and two underwent matched donor transplantation. One patient received gene therapy because of the absence of a matched donor. Opportunistic infections were prevalent, including cytomegalovirus and recurrent skin infections noted. Overall, two patients died of post-HSCT complications.

Conclusions: ADA-SCID is a life-threatening condition characterized by early severe infections and systemic manifestations. Early diagnosis and tailored treatment, including HSCT and gene therapy, are essential for improving survival outcomes. This study emphasizes the importance of early diagnosis to improve the survival and management outcomes of patients with ADA-SCID.


PDF View

References

  • Hershfield M, Tarrant T. Adenosine deaminase deficiency. GeneReviews®[Internet], 2024. google scholar
  • Grunebaum, E. et al. Updated management guidelines for adenosine deaminase deficiency. The Journal of Allergy and Clinical Immunology: In Practice, 2023. 11(6): p. 1665-1675. google scholar
  • Kuo, C.Y., et al. Adenosine deaminase (ADA)-deficient severe combined immune deficiency (SCID) in the US Immunodeficiency Network (USIDNet) Registry. Journal of clinical immunology, 2020. 40: p. 1124-1131. google scholar
  • Dqbrowska-Leonik, N. et al., National experience with adenosine deaminase deficiency related SCID in Polish children. Frontiers in Immunology, 2023. 13: p. 1058623. google scholar
  • Secord E, Hartog NL. Review of treatment for adenosine deaminase deficiency (ADA) severe combined immunodeficiency (SCID). Therapeutics and Clinical Risk Management, 2022: p. 939-944. google scholar
  • Cuvelier, G.D., et al., Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC. Blood, 2022. 140(7): p. 685-705. google scholar
  • Besci, Ö., et al. Reference values for T and B lymphocyte subpopulations in Turkish children and adults. Turkish journal of medical sciences, 2021. 51(4): p. 1814-1824. google scholar
  • Jamovi, P., Jamovi (Version 2.3)[Computer Software]. 2022. google scholar
  • Dvorak, C. C. et al. The diagnosis of severe combined immunodeficiency (SCID): the primary immune deficiency treatment consortium (PIDTC) 2022 definitions. Journal of Allergy and Clinical Immunology, 2023. 151(2): p. 539-546. google scholar
  • Baffelli, R., et al. Diagnosis, treatment and long-term follow-up of patients with ADA deficiency: a single-center experience. Journal of clinical immunology, 2015. 35: p. 624-637. google scholar
  • Baris, S., et al., The Middle East and North Africa diagnosis and management guidelines for inborn errors of immunity. The Journal of Allergy and Clinical Immunology: In Practice, 2023. 11(1): p. 158-180. e11. google scholar
  • Routes J, Verbsky J. Newborn screening for severe combined immunodeficiency. Current Allergy and Asthma Reports. 2018;18:1-7. google scholar
  • Kwan, A. et al., Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. Jama, 2014. 312(7): p. 729-738. google scholar
  • Flinn AM, Gennery AR. Adenosine deaminase deficiency: a review. Orphanet J Rare Dis., 2018. 13: p. 1-7. google scholar
  • Bradford, K.L., et al. Adenosine deaminase (ADA)-deficient severe combined immune deficiency (SCID): molecular pathogenesis and clinical manifestations. Journal of clinical immunology, 2017. 37: p. 626-637. google scholar
  • Verhagen, M. V. et al. Chest radiographs for distinguishing ADA-SCID from other forms of SCID. Journal of Clinical Immunology, 2020. 40: p. 259-266. google scholar
  • Minagawa, H., et al. Skeletal dysplasia in adenosine deaminase deficiency. Pediatrics International, 2022. 64(1): p. e15214. google scholar
  • Rogers, M. H. et al. Cognitive and behavioral abnormalities in adenosine deaminase deficient severe combined immunodeficiency. The Journal of pediatrics, 2001. 139(1): p. 44-50. google scholar
  • Kohn, D. B. et al. Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency. Journal of Allergy and Clinical Immunology, 2019. 143(3): p. 852-863. google scholar
  • Bousfiha, A., et al., The 2022 update of IUIS phenotypical classification for human inborn errors of immunity. Journal of clinical immunology, 2022. 42(7): p. 1508-1520. google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Bilgic Eltan, S., Bozkurt, S., Sefer, A.P., Yalçın Güngören, E., Yorgun Altunbaş, M., Can, S., Amirov, R., Öztürk, N., Barış, S., Özen, A., & Karakoç Aydıner, E. (2024). Evaluation of Patients with Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency: A Single-Center Experience. Journal of Child, 24(4), 219-225. https://doi.org/10.26650/jchild.2024.1584011


AMA

Bilgic Eltan S, Bozkurt S, Sefer A P, Yalçın Güngören E, Yorgun Altunbaş M, Can S, Amirov R, Öztürk N, Barış S, Özen A, Karakoç Aydıner E. Evaluation of Patients with Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency: A Single-Center Experience. Journal of Child. 2024;24(4):219-225. https://doi.org/10.26650/jchild.2024.1584011


ABNT

Bilgic Eltan, S.; Bozkurt, S.; Sefer, A.P.; Yalçın Güngören, E.; Yorgun Altunbaş, M.; Can, S.; Amirov, R.; Öztürk, N.; Barış, S.; Özen, A.; Karakoç Aydıner, E. Evaluation of Patients with Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency: A Single-Center Experience. Journal of Child, [Publisher Location], v. 24, n. 4, p. 219-225, 2024.


Chicago: Author-Date Style

Bilgic Eltan, Sevgi, and Selcen Bozkurt and Asena Pınar Sefer and Ezgi Yalçın Güngören and Melek Yorgun Altunbaş and Salim Can and Razin Amirov and Necmiye Öztürk and Safa Barış and Ahmet Özen and Elif Karakoç Aydıner. 2024. “Evaluation of Patients with Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency: A Single-Center Experience.” Journal of Child 24, no. 4: 219-225. https://doi.org/10.26650/jchild.2024.1584011


Chicago: Humanities Style

Bilgic Eltan, Sevgi, and Selcen Bozkurt and Asena Pınar Sefer and Ezgi Yalçın Güngören and Melek Yorgun Altunbaş and Salim Can and Razin Amirov and Necmiye Öztürk and Safa Barış and Ahmet Özen and Elif Karakoç Aydıner. Evaluation of Patients with Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency: A Single-Center Experience.” Journal of Child 24, no. 4 (Mar. 2025): 219-225. https://doi.org/10.26650/jchild.2024.1584011


Harvard: Australian Style

Bilgic Eltan, S & Bozkurt, S & Sefer, AP & Yalçın Güngören, E & Yorgun Altunbaş, M & Can, S & Amirov, R & Öztürk, N & Barış, S & Özen, A & Karakoç Aydıner, E 2024, 'Evaluation of Patients with Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency: A Single-Center Experience', Journal of Child, vol. 24, no. 4, pp. 219-225, viewed 10 Mar. 2025, https://doi.org/10.26650/jchild.2024.1584011


Harvard: Author-Date Style

Bilgic Eltan, S. and Bozkurt, S. and Sefer, A.P. and Yalçın Güngören, E. and Yorgun Altunbaş, M. and Can, S. and Amirov, R. and Öztürk, N. and Barış, S. and Özen, A. and Karakoç Aydıner, E. (2024) ‘Evaluation of Patients with Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency: A Single-Center Experience’, Journal of Child, 24(4), pp. 219-225. https://doi.org/10.26650/jchild.2024.1584011 (10 Mar. 2025).


MLA

Bilgic Eltan, Sevgi, and Selcen Bozkurt and Asena Pınar Sefer and Ezgi Yalçın Güngören and Melek Yorgun Altunbaş and Salim Can and Razin Amirov and Necmiye Öztürk and Safa Barış and Ahmet Özen and Elif Karakoç Aydıner. Evaluation of Patients with Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency: A Single-Center Experience.” Journal of Child, vol. 24, no. 4, 2024, pp. 219-225. [Database Container], https://doi.org/10.26650/jchild.2024.1584011


Vancouver

Bilgic Eltan S, Bozkurt S, Sefer AP, Yalçın Güngören E, Yorgun Altunbaş M, Can S, Amirov R, Öztürk N, Barış S, Özen A, Karakoç Aydıner E. Evaluation of Patients with Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency: A Single-Center Experience. Journal of Child [Internet]. 10 Mar. 2025 [cited 10 Mar. 2025];24(4):219-225. Available from: https://doi.org/10.26650/jchild.2024.1584011 doi: 10.26650/jchild.2024.1584011


ISNAD

Bilgic Eltan, Sevgi - Bozkurt, Selcen - Sefer, AsenaPınar - Yalçın Güngören, Ezgi - Yorgun Altunbaş, Melek - Can, Salim - Amirov, Razin - Öztürk, Necmiye - Barış, Safa - Özen, Ahmet - Karakoç Aydıner, Elif. Evaluation of Patients with Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency: A Single-Center Experience”. Journal of Child 24/4 (Mar. 2025): 219-225. https://doi.org/10.26650/jchild.2024.1584011



TIMELINE


Submitted17.11.2024
Accepted02.01.2025

LICENCE


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


SHARE




Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.